Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

<h4>Background</h4>Rituximab is used in the treatment of CD20+ B cell lymphomas and other B cell lymphoproliferative disorders. Its clinical efficacy might be further improved by combinations with other drugs such as statins that inhibit cholesterol synthesis and show promising antilymph...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Magdalena Winiarska, Jacek Bil, Ewa Wilczek, Grzegorz M Wilczynski, Malgorzata Lekka, Patrick J Engelberts, Wendy J M Mackus, Elzbieta Gorska, Lukasz Bojarski, Tomasz Stoklosa, Dominika Nowis, Zuzanna Kurzaj, Marcin Makowski, Eliza Glodkowska, Tadeusz Issat, Piotr Mrowka, Witold Lasek, Anna Dabrowska-Iwanicka, Grzegorz W Basak, Maria Wasik, Krzysztof Warzocha, Maciej Sinski, Zbigniew Gaciong, Marek Jakobisiak, Paul W H I Parren, Jakub Golab
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2008
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/8a6f737eb02e4bb2b26604dc216cc95b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Statins impair antitumor effects of rituximab by inducing conformational changes of CD20.

Ejemplares similares